PharmAbcine Announces First Patient Enrolled And Dosed In The Phase II Clinical Trial For The Treatment Of MTNBC

Published by
The Street

By PR Newswire DAEJEON, South Korea, Dec. 27, 2021 /PRNewswire/ — PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, today announced it has dosed the first patient in its Phase II clinical trial evaluating the combination of olinvacimab, PharmAbcine’s anti-VEGFR2 (Vascular Endothelial Growth Factor Receptors) antibody, and KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 molecule, for the treatment of mTNBC (metastatic Triple-Negative Breast Cancer) in Australia. The Phase II clinical trial is currently open an…

Read More

Leave a Reply